We are live on !
Find out more
HighMark Wealth Management Portfolio holdings
AUM
$299M
Turnover
13.67%
1-Year Est. Return
53.01%
This Fund
S&P 500
This Quarter Est. Return
+21.77%
1 Year Est. Return
+53.01%
3 Year Est. Return
+109.68%
5 Year Est. Return
+113.63%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$52.9M
(+22%)
Cap. Flow
+$8.26M
Cap. Flow % of AUM
Cap. Flow %
2.77%
Top 10 Holdings %
Top 10 Hldgs %
65.82%
Holding
600
New
46
Increased
156
Reduced
94
Closed
36
Avg Time Held
Equity + Options
3.4
years
Top 10 Avg Time Held
Equity + Options
2.7
years
Top 20 Avg Time Held
Equity + Options
2.3
years
Avg Time Held Equity only
3.4
years
Top 10 Avg Time Held Equity only
2.7
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Health Care Index ETF
FHLC
|
+$18.3M |
| 2 |
SI-BONE Inc
SIBN
|
+$3.79M |
| 3 |
Duos Technologies
DUOT
|
+$2.91M |
| 4 |
Apogee Therapeutics
APGE
|
+$2.91M |
| 5 |
Neuropace
NPCE
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$9.41M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$5.14M |
| 3 |
AnaptysBio
ANAB
|
+$3.29M |
| 4 |
iShares MSCI EAFE Value ETF
EFV
|
+$1.64M |
| 5 |
Piper Sandler
PIPR
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 64.9% |
| 2 | Healthcare | 21.84% |
| 3 | Technology | 4.77% |
| 4 | Financials | 3.58% |
| 5 | Industrials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
551
Beyond Meat
BYND
$126M
| $48 | ﹤0.01% |
2
| – | – |
2020 Q2
24 quarters
|
|
552
Heron Therapeutics
HRTX
$55.4M
| $42 | ﹤0.01% |
100
| – | – |
2025 Q1
5 quarters
|
|
553
FuboTV Inc
FUBO
$236M
| $36 | ﹤0.01% |
4
| – | – |
2023 Q3
11 quarters
|
|
554
Canopy Growth
CGC
$292M
| $28 | ﹤0.01% |
30
| – | – |
2022 Q2
16 quarters
|
|
555
X4 Pharmaceuticals
XFOR
$330M
| $28 | ﹤0.01% |
6
| – | – |
2024 Q2
8 quarters
|
|
556
Accuray
ARAY
$17.7M
| $25 | ﹤0.01% |
100
| – | – |
2019 Q4
26 quarters
|
|
557
WW International
WW
$135M
| $15 | ﹤0.01% |
1
| – | – |
2025 Q3
3 quarters
|
|
558
AquaBounty Technologies
AQB
$6.43M
| $10 | ﹤0.01% |
10
| – | – |
2025 Q2
4 quarters
|
|
559
SeaStar Medical
ICU
$11.7M
| $7 | ﹤0.01% |
2
| – | – |
2024 Q1
9 quarters
|
|
560
Patterson-UTI
PTEN
$4.79B
| $6 | ﹤0.01% |
1
| – | – |
2023 Q3
11 quarters
|
|
561
Genprex
GNPX
$1.88M
| – | – |
0
| – | – |
2024 Q4
6 quarters
|
|
562
Abivax
ABVX
$7.46B
| – | – |
-150
| Closed | -$16.7K | – |
|
563
Alcon
ALC
$35.8B
| – | – |
-40
| Closed | -$3.02K | – |
|
564
Apyx Medical
APYX
$113M
| – | – |
-5,000
| Closed | -$18.4K | – |
|
565
BJs Wholesale Club
BJ
$13.8B
| – | – |
-63
| Closed | -$6.2K | – |
|
566
Cboe Global Markets
CBOE
$36.2B
| – | – |
-35
| Closed | -$9.8K | – |
|
567
CareDx
CDNA
$4.52B
| – | – |
-475
| Closed | -$8.25K | – |
|
568
CMS Energy
CMS
$22B
| – | – |
-63
| Closed | -$4.89K | – |
|
|
CNTA
569
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-236,785
| Closed | -$9.41M | – |
|
570
Capital One
COF
$130B
| – | – |
-20
| Closed | -$3.65K | – |
|
571
Cenovus Energy
CVE
$58B
| – | – |
-45
| Closed | -$1.19K | – |
|
572
Dynatrace
DT
$16.4B
| – | – |
-133
| Closed | -$4.92K | – |
|
573
Globant
GLOB
$2.09B
| – | – |
-547
| Closed | -$25.2K | – |
|
574
Huntington Ingalls Industries
HII
$12.3B
| – | – |
-15
| Closed | -$5.7K | – |
|
575
Robinhood
HOOD
$77.7B
| – | – |
-75
| Closed | -$5.2K | – |
|
Similar funds
BOC
HighMark Wealth Management's Q2 2026 Portfolio in Review
As of Q2 2026, HighMark Wealth Management held 600 positions worth $299M, up 22% from $246M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HighMark Wealth Management's Q2 2026 filing shows 46 new, 156 increased, 94 reduced and 36 closed positions. Its largest new stake was Duos Technologies: 289,884 shares worth $3.48M. The largest sale was Centessa Pharmaceuticals, an estimated $9.41M.
By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, down from 65% a quarter earlier, followed by Healthcare and Technology.
- HighMark Wealth Management's largest Q2 2026 buy was Duos Technologies: 289,884 shares worth $3.48M.
- HighMark Wealth Management added most to Fidelity MSCI Health Care Index ETF in Q2 2026, an estimated $18.3M increase.
- HighMark Wealth Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $5.14M.
- HighMark Wealth Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $9.41M.
- HighMark Wealth Management's ten largest holdings make up 66% of its $299M portfolio in Q2 2026.
- HighMark Wealth Management opened 46 new positions and closed 36 in Q2 2026.
- HighMark Wealth Management's portfolio value rose 22% quarter-over-quarter to $299M.
Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.